Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Purchases $37,000.00 in Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Bernhardt G. Zeiher acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 20th. The stock was purchased at an average price of $3.70 per share, for a total transaction of $37,000.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $37,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Amylyx Pharmaceuticals Stock Performance

Amylyx Pharmaceuticals stock traded up $0.13 during midday trading on Monday, reaching $3.78. 400,828 shares of the company were exchanged, compared to its average volume of 1,387,702. Amylyx Pharmaceuticals, Inc. has a 1 year low of $1.58 and a 1 year high of $7.27. The company has a market capitalization of $334.92 million, a price-to-earnings ratio of -0.99 and a beta of -0.51. The firm’s 50-day simple moving average is $3.51 and its 200-day simple moving average is $4.00.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). The business had revenue of ($0.67) million for the quarter. On average, analysts forecast that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP acquired a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter valued at about $793,000. Mackenzie Financial Corp grew its position in shares of Amylyx Pharmaceuticals by 234.9% during the fourth quarter. Mackenzie Financial Corp now owns 111,310 shares of the company’s stock worth $421,000 after acquiring an additional 78,070 shares during the last quarter. Alpine Global Management LLC acquired a new stake in shares of Amylyx Pharmaceuticals in the fourth quarter valued at approximately $45,000. Two Sigma Investments LP raised its stake in Amylyx Pharmaceuticals by 77.4% during the 4th quarter. Two Sigma Investments LP now owns 651,517 shares of the company’s stock valued at $2,463,000 after acquiring an additional 284,280 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter valued at about $249,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 5th. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Amylyx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.